MAPT and Alzheimer disease: With these modalities, the National Institute on Aging and Alzheimer’s Association (NIA-AA) proposed an Aβ/tau/neurodegeneration (A/T/N) framework, and more recently inflammation/vascular/α-synuclein (I/V/S), to standardize the evaluation of biomarkers in AD research [2].